NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free LRMR Stock Alerts $8.35 -0.35 (-4.02%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$8.19▼$8.8550-Day Range$4.20▼$13.2852-Week Range$2.18▼$13.68Volume841,034 shsAverage Volume621,989 shsMarket Capitalization$366.62 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Larimar Therapeutics alerts: Email Address Larimar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.6% Upside$16.33 Price TargetShort InterestHealthy1.15% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 16 Articles This WeekInsider TradingAcquiring Shares$37.52 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.20 out of 5 starsMedical Sector376th out of 947 stocksPharmaceutical Preparations Industry176th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Larimar Therapeutics has a forecasted upside of 95.6% from its current price of $8.35.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.15% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Larimar Therapeutics has recently decreased by 18.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 2.5 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Larimar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for LRMR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows16 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 433% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $37,521,993.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -9.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -9.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Larimar Therapeutics Stock (NASDAQ:LRMR)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.Read More LRMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesMarch 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspMarch 14, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023March 14, 2024 | sfgate.comLarimar: Q4 Earnings SnapshotMarch 14, 2024 | benzinga.comRecap: Larimar Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comLarimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial ResultsMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 14, 2024 | globenewswire.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentMarch 12, 2024 | markets.businessinsider.comBuy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s AtaxiaMarch 12, 2024 | msn.com3 Best Stocks to Buy Now, 3/12/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)March 11, 2024 | finance.yahoo.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s AtaxiaMarch 11, 2024 | globenewswire.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's AtaxiaMarch 11, 2024 | msn.comLarimar Therapeutics to Present at Global Biopharma Conference in MiamiMarch 6, 2024 | globenewswire.comLarimar Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceMarch 3, 2024 | bizjournals.comLocal life sciences companies reeled in more than $750M in stock sales in first two months of 2024February 23, 2024 | finance.yahoo.comLRMR Mar 2024 17.500 callFebruary 23, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 putFebruary 22, 2024 | finance.yahoo.comLRMR Mar 2024 25.000 callFebruary 21, 2024 | markets.businessinsider.comBuy Rating Affirmed: Larimar Therapeutics’ Nomlabofusp Shows Potential in Friedreich’s Ataxia TreatmentFebruary 19, 2024 | msn.comInsider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous PurchaseFebruary 19, 2024 | finance.yahoo.comLRMR Mar 2024 15.000 putFebruary 18, 2024 | msn.comLarimar Therapeutics Raises $172.5 Million in Public Offering to Propel Rare Disease ResearchFebruary 16, 2024 | finance.yahoo.comLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesFebruary 16, 2024 | globenewswire.comLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/18/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+95.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.09% Return on Assets-33.13% Debt Debt-to-Equity RatioN/A Current Ratio15.02 Quick Ratio15.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book3.26Miscellaneous Outstanding Shares43,906,000Free Float42,018,000Market Cap$366.62 million OptionableOptionable Beta0.95 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Comp: $845.63kMr. Michael Celano CPA (Age 65)Secretary & CFO Comp: $562.62kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, Chief Medical Officer Dr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsEntrada TherapeuticsNASDAQ:TRDAOrganogenesisNASDAQ:ORGOEsperion TherapeuticsNASDAQ:ESPRSIGA TechnologiesNASDAQ:SIGAESSA PharmaNASDAQ:EPIXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 27,516 shares on 3/11/2024Ownership: 3.314%Goldman Sachs Group Inc.Sold 1,734 shares on 3/1/2024Ownership: 0.305%James E FlynnBought 4,290,617 shares on 2/16/2024Total: $37.50 M ($8.74/share)GSA Capital Partners LLPSold 63,981 shares on 2/16/2024Ownership: 0.057%Nuveen Asset Management LLCBought 2,837 shares on 2/15/2024Ownership: 0.088%View All Insider TransactionsView All Institutional Transactions LRMR Stock Analysis - Frequently Asked Questions Should I buy or sell Larimar Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks. What is Larimar Therapeutics' stock price target for 2024? 4 equities research analysts have issued twelve-month target prices for Larimar Therapeutics' shares. Their LRMR share price targets range from $10.00 to $25.00. On average, they predict the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 95.6% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts. How have LRMR shares performed in 2024? Larimar Therapeutics' stock was trading at $4.55 at the start of the year. Since then, LRMR stock has increased by 83.5% and is now trading at $8.35. View the best growth stocks for 2024 here. Are investors shorting Larimar Therapeutics? Larimar Therapeutics saw a decline in short interest in the month of February. As of February 29th, there was short interest totaling 506,800 shares, a decline of 18.0% from the February 14th total of 618,200 shares. Based on an average daily volume of 478,200 shares, the short-interest ratio is presently 1.1 days. View Larimar Therapeutics' Short Interest. When is Larimar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LRMR earnings forecast. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its earnings results on Friday, November, 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.28. Who are Larimar Therapeutics' major shareholders? Larimar Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Blue Owl Capital Holdings LP (7.78%), Verition Fund Management LLC (6.40%), Vanguard Group Inc. (3.31%), Vanguard Group Inc. (3.31%), Opaleye Management Inc. (1.42%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LRMR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.